Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 Weeks of therapy are sufficient for HCV genotype 2 and 3;Therapie der chronischen hepatitis C mit PEG-interferon alpha-2b und ribavirin: 24 Wochen behandlung sind ausreichend bei HCV-genotyp 2 und 3

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 6, 2003, Pages 517-522

  Cornberg, M ^a   Huppe D ^b   Wiegand, J ^a   Felten, G ^b   Wedemeyer, H ^a   Manns, M P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Gastroenterologische Fachpraxis   (Germany)

Author keywords

Chronic hepatitis C; HCV genotype; PEG Interferon alpha; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; THROMBOCYTOPENIA; VIRUS TYPING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MULTICENTER STUDIES; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TIME FACTORS;

EID: 0038787878     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39649     Document Type: Article

References (11)

1. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432
2. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492
3. Cornberg M, Wedemeyer H, Manns MP. Treatment of Chronic Hepatitis C with PEGylated Interferon and Ribavirin. Curr Gastroenterol Rep 2002; 4: 23-30
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
5. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
6. Hadziyannis SJ, Cheinquer H, Morgan T et al. Peg-Interferon alpha-2a (40KD) (PEGASYS®) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double blind, multicentre study examining effect and duration of treatment and RBV dose. J Hepatol 2002; 36: 3
7. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403
8. Seeff LB, Hoofnagle JH. National institutes of health consensus development conference: management of hepatitis C: 2002. Hepatology 2002; 36
9. Poynard T, McHutchison J, Goodman Z et al. Is an "a la carte" combination interferon alpha-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000: 31: 211-218
10. Hinrichsen H, Buggisch P, Nasser S et al. A prospective randomised 24 week trial of peg-interferon alpha-2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients. Hepatology 2002; 36: 311A
11. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069